We are excited to announce a major advancement in cancer treatment with the development of a novel therapy targeting oncogenic KRAS mutations using our BactPac™ platform. This pioneering approach utilizes engineered bacteria to deliver a potent single-domain antibody (nanobody) that targets a wide spectrum of KRAS mutations, offering a potential treatment option for a broad range of patients.

Our cutting-edge therapy is designed to tackle KRAS-driven cancers, including pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), and non-small cell lung cancer (NSCLC). In preclinical studies, our therapeutic candidate, SVC-KRAb, showed remarkable efficacy in human cancer cell xenograft mouse models, achieving up to an 80% reduction in tumor volumes compared to untreated controls. These results were consistent across both intravenous and intratumoral dosing.

This marks the first successful targeting of non-G12C KRAS mutations, representing a significant breakthrough in the fight against KRAS-mutant cancers.

In a major triumph, SiVEC has secured victory in the highly competitive National Institutes of Health (NIH) TARGETED (Targeted Genome Editor Delivery) Challenge. The competition, designed to propel advancements in genome editing technology by sourcing innovative solutions for delivering genome editors to somatic cells, witnessed SiVEC rise to the occasion with unparalleled expertise. This remarkable accomplishment marks a significant stride forward in the ongoing pursuit of revolutionizing gene editing for the treatment of genetic diseases at their source.

Host Lori Jones and Lyndsey dive into her journey of co-founding SiVEC, a game-changing biotech company with a groundbreaking drug delivery platform, and how the team is making waves in the industry as a top emerging company. The interview also talks about the incredible ecosystem supporting technology development in Colorado! Join us for this exciting conversation about commercializing science, acquiring business acumen, and embracing a risk-taking mindset.

As a visionary health innovator who is passionate about building and growing successful life sciences companies in Colorado, Lyndsey is honored to be recognized as a respected leader in the life science’s community. She looks forward to beginning this new endeavor where she will work closely with CBSA, CBSA members, and Colorado’s life science community as they continue to gain momentum and advance Colorado’s life science ecosystem to the top 5!

Our exceptional team at SiVEC Biotechnologies has reached yet another milestone! The grant awarded by the Colorado Office of Economic Development and International Trade is a testament to SiVEC’s hard work and dedication to their mission of advancing nucleic acid and gene therapies with a focus on safe and precise tissue-targeted delivery. This $250,000 grant will enable SiVEC to advance a first-in-class cancer therapeutic targeting oncogenic-KRAS into IND-enabling stages.

The Innovator’s Pitch Challenge allows early-stage companies to gain additional exposure to conference attendees and pitch directly to a panel of active investors and industry experts.

The March event, a perennial highlight of RESI, featured more than 34 competing companies. Among the presenters, Dr. Lyndsey Linke (SiVEC CEO) was awarded the first place prize.

The new publication, published on February 5, 2023, appears in the journal Engineering in Life Sciences.

SiVEC's CEO Lyndsey Linke participated in the BIO International Start-Up Stadium, a competition featuring live pitches from 42 finalist companies.